NASDAQ:VVOS Vivos Therapeutics Q1 2026 Earnings Report $0.57 -0.04 (-6.79%) Closing price 04:00 PM EasternExtended Trading$0.57 -0.01 (-0.87%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vivos Therapeutics EPS ResultsActual EPS-$0.52Consensus EPS -$0.45Beat/MissMissed by -$0.07One Year Ago EPSN/AVivos Therapeutics Revenue ResultsActual Revenue$5.14 millionExpected Revenue$4.35 millionBeat/MissBeat by +$792.00 thousandYoY Revenue GrowthN/AVivos Therapeutics Announcement DetailsQuarterQ1 2026Date5/20/2026TimeAfter Market ClosesConference Call DateWednesday, May 20, 2026Conference Call Time4:00PM ETUpcoming EarningsVivos Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 18, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vivos Therapeutics Earnings HeadlinesVivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights OfferingJune 11 at 8:30 AM | globenewswire.comVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to ...June 10 at 9:42 AM | markets.businessinsider.comThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the world's largest fund managers - including a section naming one small company Musk's Colossus cannot operate without. Right now, most fund managers have never heard of it. By Friday, every one of them will. Dylan Jovine has identified the name and ticker before $75 billion in new capital starts chasing the SpaceX supply chain.June 12 at 1:00 AM | Behind the Markets (Ad)Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular PatientsJune 10 at 9:03 AM | globenewswire.comVivos Therapeutics, Inc. to Present at The Small Cap Showcase & WTR Insights on June 9, 2026June 8, 2026 | quiverquant.comQVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026June 8, 2026 | globenewswire.comSee More Vivos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vivos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivos Therapeutics and other key companies, straight to your email. Email Address About Vivos TherapeuticsVivos Therapeutics (NASDAQ:VVOS) is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means. The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol. Clinicians are guided through patient assessment, imaging and diagnostic procedures, appliance design and fitting, and ongoing monitoring. In addition to device manufacturing, Vivos Therapeutics provides comprehensive training and certification programs for dental professionals, enabling a standardized approach to screening, treatment planning, and patient follow-up within the Vivos network. Headquartered in Lone Tree, Colorado, Vivos Therapeutics markets its solutions through a network of licensed dental practitioners across the United States and select international regions, including Canada, Europe and parts of Asia-Pacific. The company continues to expand its footprint by partnering with accredited educational institutions and professional societies to promote awareness of oral appliance therapy as a first-line intervention for airway health.View Vivos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Why Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors EarsCracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressChewy’s Growth Engine Is Stronger Than the Market ThinksCasey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance AlignThe “Duck Stock” Keeps Quietly Making Money for Shareholders Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
